Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 251 Bayview Boulevard, Baltimore, MD 21224, USA.
Drug Alcohol Depend. 2013 Aug 1;131(3):258-62. doi: 10.1016/j.drugalcdep.2012.11.014. Epub 2012 Dec 14.
Prescribed sublingual (SL) buprenorphine is sometimes diverted for intravenous (IV) abuse, but no human pharmacokinetic data are available following high-dose IV buprenorphine.
Plasma was collected for 72 h after administration of placebo or 2, 4, 8, 12, or 16 mg IV buprenorphine in escalating order (single-blind, double-dummy) in 5 healthy male non-dependent opioid users. Buprenorphine and its primary active metabolite, norbuprenorphine, were quantified by liquid chromatography-tandem mass spectrometry with limits of quantitation of 0.1 μg/L.
Maximum buprenorphine concentrations (mean ± SE) were detected 10 min after 2, 4, 8, 12, 16 mg IV: 19.3 ± 1.0, 44.5 ± 4.8, 85.2 ± 7.7, 124.6 ± 16.6, and 137.7 ± 18.8 μg/L, respectively. Maximum norbuprenorphine concentrations occurred 10-15 min (3.7 ± 0.7 μg/L) after 16 mg IV administration.
Buprenorphine concentrations increased in a significantly linear dose-dependent manner up to 12 mg IV buprenorphine. Thus, previously demonstrated pharmacodynamic ceiling effects (over 2-16 mg) are not due to pharmacokinetic adaptations within this range, although they may play a role at doses higher than 12 mg.
处方舌下(SL)丁丙诺啡有时会被转移用于静脉内(IV)滥用,但尚无人类药代动力学数据可用于高剂量 IV 丁丙诺啡后。
在 5 名健康的非依赖阿片类药物男性使用者中,以递增顺序(单盲,双盲)单次给予安慰剂或 2、4、8、12 或 16 mg IV 丁丙诺啡后,收集 72 小时的血浆。丁丙诺啡及其主要活性代谢物去甲丁丙诺啡通过液相色谱-串联质谱法进行定量,定量下限为 0.1 μg/L。
10 分钟后检测到最大丁丙诺啡浓度(平均值±SE):2、4、8、12、16 mg IV 分别为 19.3±1.0、44.5±4.8、85.2±7.7、124.6±16.6 和 137.7±18.8μg/L。最大去甲丁丙诺啡浓度在 16 mg IV 给药后 10-15 分钟出现(3.7±0.7μg/L)。
丁丙诺啡浓度呈显著线性剂量依赖性增加,直至 12 mg IV 丁丙诺啡。因此,先前表现出的药效学上限效应(2-16 mg 之间)不是由于在此范围内的药代动力学适应引起的,尽管它们在剂量高于 12 mg 时可能起作用。